New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2014
07:44 EDTBAX, ONTXRigosertib failure removes positive catalyst for Baxter, says Leerink
Leerink says Onconova's (ONTX) announcement last night that pivotal results of IV rigosertib in myelodysplastic syndrome failed to meet its primary endpoint as removing a positive catalyst for Baxter (BAX) since Baxter has the European rights to rigosertib. Leerink points out that Baxter had previously noted that rigosertib could ultimately be a $1B drug. However, the firm believes rigosertib was largely not reflected in estimates for Baxter and it reiterates an Outperform rating on the stock.
News For BAX;ONTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
07:37 EDTBAXStifel to hold a conference
Subscribe for More Information
November 13, 2014
16:06 EDTONTXOnconova reports Q3 EPS (69c), consensus (75c)
Reports Q3 revenue $114K, consensus $0. Cash, cash equivalents, and marketable securities as of September 30 totaled $57.3M.
November 12, 2014
08:02 EDTBAXCredit Suisse to hold a conference
Subscribe for More Information
07:27 EDTBAXNorth American Spine Society to hold annual meeting
Subscribe for More Information
November 10, 2014
15:54 EDTBAXAmerican Society of Nephrology to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use